Trial Profile
Phase II Study Of Cisplatin, Gemcitabine, And ZD 1839 (IRESSA) (IND 61187; NSC 715055) For The Treatment Of Advanced Urothelial Tract Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Cisplatin; Gemcitabine
- Indications Bladder cancer
- Focus Therapeutic Use
- 26 May 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
- 26 May 2009 Inclusion and exclusion criteria amended from NCT.
- 26 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.